Show simple item record

dc.contributor.authorMatutes, E
dc.date.accessioned2018-08-30T13:47:11Z
dc.date.issued2007-12
dc.identifier12
dc.identifier.citationJOURNAL OF CLINICAL PATHOLOGY, 2007, 60 pp. 1373 - 1377
dc.identifier.issn0021-9746
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2451
dc.identifier.doi10.1136/jcp.2007.052456
dc.description.abstractAdult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution. The disease manifests with leukaemia in greater than two thirds of patients, while the remaining patients have a lymphomatous form. According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma. Organomegaly, skin involvement, circulating atypical lymphocytes (”flower” cells) with a CD4+ CD25+ phenotype and hypercalcaemia are the most common disease features. The diagnosis should be based on a constellation of clinical features and laboratory investigations. The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I. The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sezary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease. The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms. Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas. The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate. Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.
dc.format.extent1373 - 1377
dc.languageeng
dc.language.isoeng
dc.publisherB M J PUBLISHING GROUP
dc.titleAdult T-cell leukaemia/lymphoma
dc.typeJournal Article
rioxxterms.versionofrecord10.1136/jcp.2007.052456
rioxxterms.licenseref.startdate2007-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJOURNAL OF CLINICAL PATHOLOGY
pubs.notesaffiliation: Matutes, E (Reprint Author), Royal Marsden NHS Trust, Inst Canc Res, Haematol Oncol Unit, 203 Fulham Rd, London SW3 6JJ, England. Royal Marsden NHS Trust, Inst Canc Res, Haematol Oncol Unit, London SW3 6JJ, England. keywords-plus: LEUKEMIA-LYMPHOMA; HTLV-I; COMPLETE RESPONSE; INTERFERON-ALFA; LEUKEMIA/LYMPHOMA; TRANSPLANTATION; THERAPY; DISEASE; CLASSIFICATION; COMBINATION research-areas: Pathology web-of-science-categories: Pathology author-email: [email protected] number-of-cited-references: 42 times-cited: 70 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: J. Clin. Pathol. doc-delivery-number: 235MR unique-id: ISI:000251238900012 oa: green_published da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume60en_US
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record